Assessment of therapeutic response in patients with metastatic bone disease.
AffiliationCancer Research UK, Department of Medical Oncology, Christie Hospital, Manchester, UK.
MetadataShow full item record
AbstractMetastatic bone disease is common in cancer patients and causes substantial disease-related morbidity and mortality. However, several effective treatments are available for the management of these patients. Bisphosphonates, which inhibit osteoclast-mediated resorption of bone matrix, are especially important because they decrease the incidence of skeletal-related events in many tumour types and can complement antineoplastic therapies. At present, assessment of treatment for bone metastases is hindered by a lack of effective, rapid methods to measure disease response. We discuss the difficulties of current measures of response assessment and describe the development of new radiological and biochemical markers of bone metastases. Assays that detect type I collagen telopeptides as markers of bone resorption seem to be most promising at present.
CitationAssessment of therapeutic response in patients with metastatic bone disease. 2004, 5 (10):607-16 Lancet Oncol.
JournalThe Lancet Oncology
- Clinical trials in metastatic breast cancer to bone: past--present--future.
- Authors: Body JJ
- Issue date: 1995 Dec
- Bone imaging in metastatic breast cancer.
- Authors: Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT
- Issue date: 2004 Jul 15
- Markers of bone turnover in bone metastases.
- Authors: Fontana A, Delmas PD
- Issue date: 2000 Jun 15
- The use of molecular markers of bone turnover in the management of patients with metastatic bone disease.
- Authors: Seibel MJ
- Issue date: 2008 Jun
- Bisphosphonates for breast cancer.
- Authors: Pavlakis N, Schmidt R, Stockler M
- Issue date: 2005 Jul 20